Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10754294rdf:typepubmed:Citationlld:pubmed
pubmed-article:10754294lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0282552lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0538072lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0539791lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1512505lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0035015lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1332682lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1332686lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1704869lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1882923lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C1548437lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:10754294lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:10754294pubmed:issue8lld:pubmed
pubmed-article:10754294pubmed:dateCreated2000-5-9lld:pubmed
pubmed-article:10754294pubmed:abstractTextCK beta-11 chemoattracts T cells, B cells, dendritic cells, macrophage progenitors, and NK cells and facilitates dendritic cell and T cell interactions in secondary lymphoid tissues. We hypothesized that expression of CK beta-11 in tumor cells may generate antitumor immunity through these interactions. After transduction with the retroviral vector L(CK beta 11)SN, the murine breast cancer cell line C3L5 (C3L5-CK beta 11) showed expression of retroviral mRNA by Northern analysis and production of functional CK beta-11 by chemotaxis of human NK cells to C3L5-CK beta 11 supernatant. Only 10% of mice injected with C3L5-CK beta 11 developed tumors, compared with 100% of mice injected with a transduced control C3L5 line (C3L5-G1N). Importantly, the in vitro growth characteristics of the CK beta-11-transduced cell line were unaffected, suggesting the difference in growth in vivo was a result of chemokine production. Vaccination with C3L5-CK beta 11 partially protected animals from parental C3L5 challenge. Immunodepletion with anti-asialo-GM1 or anti-CD4 during C3L5-CK beta 11 vaccination significantly reduced CK beta-11 antitumor activity compared with control and anti-CD8-treated groups. Splenocytes from NK-depleted animals transferred the acquired immunity generated with C3L5-CK beta 11 vaccination, while splenocytes from the CD4-depleted animals did not. These results indicate, for the first time, that expression of CK beta-11 in a breast cancer cell line mediates rejection of the transduced tumor through a mechanism involving NK and CD4+ cells. Furthermore, CK beta-11-transduced tumor cells generate long-term antitumor immunity that requires CD4+ cells. These studies demonstrate the potential role of CK beta-11 as an adjuvant in stimulating antitumor responses.lld:pubmed
pubmed-article:10754294pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:languageenglld:pubmed
pubmed-article:10754294pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10754294pubmed:statusMEDLINElld:pubmed
pubmed-article:10754294pubmed:monthAprlld:pubmed
pubmed-article:10754294pubmed:issn0022-1767lld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:KaplanM HMHlld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:BroxmeyerH...lld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:KimC HCHlld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:FORTD JDJlld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:CornettaKKlld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:BreenG EGElld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:FosterR GRGlld:pubmed
pubmed-article:10754294pubmed:authorpubmed-author:HromasRRlld:pubmed
pubmed-article:10754294pubmed:issnTypePrintlld:pubmed
pubmed-article:10754294pubmed:day15lld:pubmed
pubmed-article:10754294pubmed:volume164lld:pubmed
pubmed-article:10754294pubmed:ownerNLMlld:pubmed
pubmed-article:10754294pubmed:authorsCompleteYlld:pubmed
pubmed-article:10754294pubmed:pagination4025-31lld:pubmed
pubmed-article:10754294pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:meshHeadingpubmed-meshheading:10754294...lld:pubmed
pubmed-article:10754294pubmed:year2000lld:pubmed
pubmed-article:10754294pubmed:articleTitleThe CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.lld:pubmed
pubmed-article:10754294pubmed:affiliationDepartments ofMicrobiology/Immunology and Medicine (Hematology/Oncology), and Walther Oncology Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA. stephen_braun@hms.harvard.edulld:pubmed
pubmed-article:10754294pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10754294pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10754294pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10754294lld:pubmed